These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 28920959)

  • 41. Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes.
    Anusha ; Dalal H; Subramanian S; V P S; Gowda DA; H K; Damodar S; Vyas N
    Cell Death Dis; 2021 Mar; 12(3):259. PubMed ID: 33707419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.
    Fathy El-Metwaly N; Aref S; Ayed M; Abdel Hamid M; El-Sokkary AMA
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3237-3243. PubMed ID: 34711000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
    Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
    Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
    Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
    Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
    Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cotylenin A and tyrosine kinase inhibitors synergistically inhibit the growth of chronic myeloid leukemia cells.
    Ikejiri F; Honma Y; Okada T; Urano T; Suzumiya J
    Int J Oncol; 2018 Jun; 52(6):2061-2068. PubMed ID: 29620253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
    Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B
    J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
    Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
    Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    El Eit R; Itani AR; Nassar F; Rasbieh N; Jabbour M; Santina A; Zaatari G; Mahon FX; Bazarbachi A; Nasr R
    Cancer; 2019 Aug; 125(16):2818-2828. PubMed ID: 31034603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.
    Miyauchi M; Koya J; Arai S; Yamazaki S; Honda A; Kataoka K; Yoshimi A; Taoka K; Kumano K; Kurokawa M
    Stem Cell Reports; 2018 Mar; 10(3):1115-1130. PubMed ID: 29429960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
    Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
    Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
    Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.
    Rattigan KM; Brabcova Z; Sarnello D; Zarou MM; Roy K; Kwan R; de Beauchamp L; Dawson A; Ianniciello A; Khalaf A; Kalkman ER; Scott MT; Dunn K; Sumpton D; Michie AM; Copland M; Tardito S; Gottlieb E; Vignir Helgason G
    Nat Commun; 2023 Aug; 14(1):4634. PubMed ID: 37591854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
    Sinnakannu JR; Lee KL; Cheng S; Li J; Yu M; Tan SP; Ong CCH; Li H; Than H; Anczuków-Camarda O; Krainer AR; Roca X; Rozen SG; Iqbal J; Yang H; Chuah C; Ong ST
    Leukemia; 2020 Jul; 34(7):1787-1798. PubMed ID: 32051529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
    Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
    Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.